Advances in prodrug design.
The background of prodrug design is presented herein as the basis for introducing new and advanced latent systems, taking into account mainly the versatility of polymers and other macromolecules as carriers. PDEPT (Polymer-Directed Enzyme Prodrug Therapy); PELT (Polymer-Enzyme Liposome Therapy); CDS (Chemical Delivery System); ADEPT(Antibody-Directed Enzyme Prodrug Therapy); GDEPT/VDEPT (Gene-Directed Enzyme Prodrug Therapy/Virus-Directed Enzyme Prodrug Therapy); ODDS (Osteotropic Drug Delivery System) and LEAPT (Lectin-directed enzyme-activated prodrug therapy) are briefly described and some examples are given.
Silva
Antonio Távora de Albuquerque
AT
Laboratório de Pesquisa e Desenvolvimento de Fármacos, Departamento de Fármacos e Medicamentos, Faculdade de Ciencias Farmacee, UNESP, Araraquara, Brazil.
Chung
Man Chin
MC
Castro
Lúcia Fioravanti
LF
Güido
Rafael Victorio Carvalho
RV
Ferreira
Elizabeth Igne
EI
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D004337:Drug Carriers; D016503:Drug Delivery Systems; D015195:Drug Design; D015316:Genetic Therapy; D006801:Humans; D037102:Lectins / Q000627:therapeutic use; D046911:Macromolecular Substances / Q000008:administration & dosage* / Q000378:metabolism; D010024:Osteoporosis / Q000188:drug therapy; D011355:Prodrugs / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D014780:Viruses / Q000276:immunology
D000906:Antibodies; D004337:Drug Carriers; D037102:Lectins; D046911:Macromolecular Substances; D011355:Prodrugs